BMS's Attachment Inhibitor Shows Promise

A promising trial of Bristol-Myers Squibb's investigational attachment inhibitor GS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports.

http://ift.tt/1lTUUz0